BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $834 | -5.7% | 12,256 | +13.1% | 0.01% | -7.1% |
| Q2 2023 | $884 | +18.7% | 10,835 | +8.0% | 0.01% | +7.7% |
| Q1 2023 | $745 | -99.9% | 10,036 | -20.7% | 0.01% | -31.6% |
| Q4 2022 | $1,049,000 | -99.9% | 12,652 | +299.7% | 0.02% | +5.6% |
| Q3 2022 | $899,000,000 | +87181.6% | 3,165 | +6.5% | 0.02% | -10.0% |
| Q2 2022 | $1,030,000 | -22.8% | 2,971 | -3.5% | 0.02% | -13.0% |
| Q1 2022 | $1,334,000 | -99.9% | 3,080 | -6.3% | 0.02% | -23.3% |
| Q4 2021 | $1,700,000,000 | +106017.4% | 3,287 | -0.5% | 0.03% | -6.2% |
| Q3 2021 | $1,602,000 | +14.9% | 3,305 | +6.7% | 0.03% | +6.7% |
| Q2 2021 | $1,394,000 | +21.5% | 3,097 | +3.2% | 0.03% | +7.1% |
| Q1 2021 | $1,147,000 | +38.5% | 3,002 | +15.1% | 0.03% | +21.7% |
| Q4 2020 | $828,000 | +40.3% | 2,608 | +9.5% | 0.02% | +15.0% |
| Q3 2020 | $590,000 | +9.1% | 2,381 | +16.1% | 0.02% | 0.0% |
| Q2 2020 | $541,000 | +78.0% | 2,050 | +28.0% | 0.02% | -23.1% |
| Q1 2020 | $304,000 | +7.0% | 1,602 | +23.8% | 0.03% | +116.7% |
| Q4 2019 | $284,000 | – | 1,294 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $13,206,000 | 5.33% |
| Montanaro Asset Management Ltd | 101,950 | $28,954,000 | 4.43% |
| Jackson Square Partners, LLC | 521,991 | $148,245,000 | 3.89% |
| Sandhill Capital Partners LLC | 119,671 | $33,987,000 | 3.88% |
| STONE RUN CAPITAL, LLC | 22,055 | $6,264,000 | 3.38% |
| Ownership Capital B.V. | 610,466 | $173,372,000 | 3.35% |
| Brown Capital Management | 823,303 | $233,818,000 | 3.28% |
| DF DENT & CO INC | 671,348 | $190,663,000 | 2.94% |
| Westwind Capital | 27,931 | $7,932,000 | 2.78% |
| MAIRS & POWER INC | 673,620 | $191,308,000 | 2.41% |